Renowned luminaries in Personalized Medicine
Groundbreaking companies with emerging technologies
More than 1300 peers from around the globe
70 sessions in 4 parallel tracks


NGS And Clinical Interplay

The adoption of Personalized Medicine is in part being driven by the omnipresence of Next-Generation Sequencing (NGS) and the fast-paced technological innovations. As a result, we can see the clinical sector responding with voicing their needs, and the industry adapting to deliver solutions that change clinical medicine and healthcare into a patient-centered care. This panel will focus on clinical requirements, new advancements, and the different challenges they encounter to advance genomics into the clinic.


Allison Ballmer

Allison Ballmer, International Business Leader, Global Marketing Strategy, Roche Sequencing

Allison Ballmer is International Business Leader at Roche Sequencing, leading the Global Marketing Strategy and Lifecycle Plan for Roche’s Next Generation technology.  Prior to joining Roche, Ballmer lead the Global Marketing and Commercialization for Swiss-based Molecular Diagnostics arm of Biocartis.


Clifford Reid, Ph.D., CEO, Complete Genomics

Clifford A. Reid, Ph.D., is co-founder of Complete Genomics and has served as President, Chief Executive Officer and Chairman since July 2005 and as a member of the board of directors since July 2005. From March 2003 to September 2005, Dr. Reid was Vice President of Collaborative Solutions at Open Text Corporation, a software company. Read Full Bio

Richard Klausner, M.D., Chief Medical Officer & Interim General Manager, Oncology, Illumina

Richard (Rick) Klausner joined Illumina as Chief Medical Officer in September 2013. Rick is responsible for Illumina’s strategies for advancing genomics into clinical medicine and public health. He is also part of Illumina’s executive management team, which is responsible for directing all aspects of company strategy, planning and operations. Read Full Bio


Stefan Roever, Co-founder & CEO, Genia Technologies

Stefan Roever has a broad entrepreneurial, software, and finance background. He was Co-Founder and CEO of Brokat Technologies, an encryption banking software company. Brokat reached a several billion dollar market cap and went public in 1998 on the Frankfurt Stock Exchange and on NASDAQ in 2000. Read Full Bio

Jonas Korlach, Ph.D., Chief Scientific Officer, Pacific Biosciences

Dr. Korlach was appointed Chief Scientific Officer at Pacific Biosciences in July, 2012. He was previously Scientific Fellow, supporting commercial development of the PacBio® RS system and performing research aimed at developing new applications for Single Molecule, Real-Time (SMRT®) technologies, such as DNA base modification detection. Read Full Bio

Peter Yu

Peter Paul Yu, M.D., President, Asco

Peter Paul Yu, MD, FACP, FASCO, is a medical oncologist and hematologist and Director of Cancer Research at Palo Alto Medical Foundation, where he worked since 1989. In addition to his role as the 2014-2015 President of ASCO, Dr. Yu also serves on the Scientific Program, Nominating, Government Relations, and Special Awards Selection Committees. Read Full Bio


Web Analytics